Depoxevis-30

Description

Depoxevis-30 is an ANVIS product containing dapoxetine 30 mg. The photographed carton identifies the dosage form as tablets and contains 1 × 4 tablets (4 tablets). This entry records the visible packaging details and provides general ingredient information.

Depoxevis-30 product specification

• Product name: Depoxevis-30
• Ingredient: Dapoxetine
• Labelled strength: 30 mg
• Dosage form: Tablets
• Pack presentation: 1 × 4 tablets (4 tablets)
• Brand: ANVIS

First, match the full name, strength and formulation to the item supplied. For example, a different strength needs separate identification. The pack quantity describes the carton contents, not a daily dose or treatment duration. Therefore, review the supplied leaflet and the prescription before use.

General information about dapoxetine

Dapoxetine is an SSRI used for diagnosed premature ejaculation in adult men. A clinician must confirm the diagnosis and assess whether treatment is appropriate. It is not a general sexual-performance supplement. Therefore, do not choose it solely from the strength or pack appearance.

Depoxevis-30: important precautions

Dapoxetine can cause dizziness, low blood pressure and fainting. Avoid alcohol because it can increase these effects and the risk of injury. Also report heart problems, previous fainting, liver disease, mania or severe depression before treatment. Do not drive or operate machinery if you feel dizzy or faint.

Medicine interactions can be serious. In particular, do not combine dapoxetine with antidepressants, tramadol, St John’s wort or other interacting treatments without specialist review. Tell your clinician about all medicines and supplements. Seek urgent medical advice after fainting or a serious reaction. Follow the supplied leaflet for full restrictions.

Documentation and product enquiries

The MHRA-hosted dapoxetine reference leaflet provides background on the ingredient rather than the complete specification of this ANVIS product. Read it alongside the leaflet supplied with your pack. For further Depoxevis-30 documentation, contact ANVIS with the name and strength. Alternatively, browse our tablet catalogue.